Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

The Burden of Psoriasis in Canada: Insights from the pSoriasis Knowledge IN Canada (SKIN) Survey

(2015) Charles W. Lynde et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

(2010) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

(2010) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis and the Risk of Diabetes and Hypertension

(2009) Abrar A. Qureshi et al.   ARCHIVES OF DERMATOLOGY

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

(2009) M. Lebwohl et al.   BRITISH JOURNAL OF DERMATOLOGY

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

(2009) Kristian Reich et al.   DERMATOLOGY

Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis

(2009) Paolo Gisondi et al.   JOURNAL OF HEPATOLOGY

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

(2008) M. Augustin et al.   DERMATOLOGY

Association between Psoriasis and the Metabolic Syndrome

(2008) A.D. Cohen et al.   DERMATOLOGY

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

(2008) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY